Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Honghui Zhou

Showing results (81-90 of 143) with videos related to

Pageof 15
Sort By:
Journal of Clinical Pharmacology|February 7, 2020
Population Pharmacokinetics and Exposure-Response Modeling Analyses of Ustekinumab in Adults With Moderately to Severely Active Ulcerative ColitisYan Xu, Chuanpu Hu, Yang Chen, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 9, 2018
Development and Translational Application of a Minimal Physiologically Based Pharmacokinetic Model for a Monoclonal Antibody against Interleukin 23 (IL-23) in IL-23-Induced Psoriasis-Like MiceXi Chen, Xiling Jiang, Rajitha Doddareddy, et al.
Journal of Clinical Pharmacology|April 11, 2008
Population pharmacokinetics of infliximab in patients with ankylosing spondylitisZhenhua Xu, Kathleen Seitz, Adedigbo Fasanmade, et al.
Clinical and Translational Science|December 2, 2021
Population pharmacokinetics and exposure-response modeling analyses of guselkumab in patients with psoriatic arthritisYang Chen, Xin Miao, Chyi-Hung Hsu, et al.
The AAPS Journal|August 4, 2020
Application of Trial Simulation in the Design of a Prospective Study for Concentration-QTc Analysis in Support of a Thorough QT Study WaiverPeijuan Zhu, Chyi-Hung Hsu, Chuanpu Hu, et al.
Journal of Clinical Pharmacology|January 18, 2018
Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL-23, in Patients with Moderate to Severe Plaque PsoriasisZhenling Yao, Chuanpu Hu, Yaowei Zhu, et al.
Clinical and Translational Science|May 15, 2020
Evaluating Potential Disease-Mediated Protein-Drug Interactions in Patients With Moderate-to-Severe Plaque Psoriasis Receiving Subcutaneous GuselkumabYaowei Zhu, Yan Xu, Yanli Zhuang, et al.
European Journal of Clinical Pharmacology|September 17, 2009
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitisAdedigbo A Fasanmade, Omoniyi J Adedokun, Joyce Ford, et al.
Pharmaceutical Statistics|January 29, 2020
A novel quantification of information for longitudinal data analyzed by mixed-effects modelingMin Yuan, Yi Li, Yaning Yang, et al.
British Journal of Clinical Pharmacology|March 10, 2018
Full covariate modelling approach in population pharmacokinetics: understanding the underlying hypothesis tests and implications of multiplicityXu Steven Xu, Min Yuan, Hao Zhu, et al.
Pageof 15

Showing results (81-90 of 143) with videos related to

Sort By:
Pageof 15
Journal of Clinical Pharmacology|February 7, 2020
Population Pharmacokinetics and Exposure-Response Modeling Analyses of Ustekinumab in Adults With Moderately to Severely Active Ulcerative ColitisYan Xu, Chuanpu Hu, Yang Chen, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 9, 2018
Development and Translational Application of a Minimal Physiologically Based Pharmacokinetic Model for a Monoclonal Antibody against Interleukin 23 (IL-23) in IL-23-Induced Psoriasis-Like MiceXi Chen, Xiling Jiang, Rajitha Doddareddy, et al.
Journal of Clinical Pharmacology|April 11, 2008
Population pharmacokinetics of infliximab in patients with ankylosing spondylitisZhenhua Xu, Kathleen Seitz, Adedigbo Fasanmade, et al.
Clinical and Translational Science|December 2, 2021
Population pharmacokinetics and exposure-response modeling analyses of guselkumab in patients with psoriatic arthritisYang Chen, Xin Miao, Chyi-Hung Hsu, et al.
The AAPS Journal|August 4, 2020
Application of Trial Simulation in the Design of a Prospective Study for Concentration-QTc Analysis in Support of a Thorough QT Study WaiverPeijuan Zhu, Chyi-Hung Hsu, Chuanpu Hu, et al.
Journal of Clinical Pharmacology|January 18, 2018
Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL-23, in Patients with Moderate to Severe Plaque PsoriasisZhenling Yao, Chuanpu Hu, Yaowei Zhu, et al.
Clinical and Translational Science|May 15, 2020
Evaluating Potential Disease-Mediated Protein-Drug Interactions in Patients With Moderate-to-Severe Plaque Psoriasis Receiving Subcutaneous GuselkumabYaowei Zhu, Yan Xu, Yanli Zhuang, et al.
European Journal of Clinical Pharmacology|September 17, 2009
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitisAdedigbo A Fasanmade, Omoniyi J Adedokun, Joyce Ford, et al.
Pharmaceutical Statistics|January 29, 2020
A novel quantification of information for longitudinal data analyzed by mixed-effects modelingMin Yuan, Yi Li, Yaning Yang, et al.
British Journal of Clinical Pharmacology|March 10, 2018
Full covariate modelling approach in population pharmacokinetics: understanding the underlying hypothesis tests and implications of multiplicityXu Steven Xu, Min Yuan, Hao Zhu, et al.
Pageof 15